Clinical Research

KOWA Research Institute Study: A Phase 3, prospective, double-masked, randomized, multi-center, vehicle-controlled, parallel-group, 12-week administration and 40 – week extension study confirming the efficacy and safety of K-161 Ophthalmic Solution for the treatment of moderate to severe dry eye disease.
Click here for more information.